Tirzepatide vs Semaglutide:
Key differences comparison

Head-to-head trial result

SURMOUNT-5 found tirzepatide produced about 20% average body weight loss versus roughly 14% for semaglutide over 72 weeks in adults with obesity. Broader pooled analyses across multiple trials show a similar pattern, at roughly −11.4% versus −7.3%, and a large real-world cohort study (Truveta) found about −11.2% versus −8.8% at 6 months.

More people hit bigger weight-loss milestones

A larger share of tirzepatide users reach 10%, 15%, and 20%+ total weight loss than semaglutide users at comparable time points, though plenty of people reach those same milestones on semaglutide too — individual response varies a lot.

Why the gap exists

Tirzepatide's added GIP receptor activity is thought to enhance insulin sensitivity and fat metabolism beyond what GLP-1 activation alone achieves.

Shared GI side effects

Nausea, diarrhea, constipation, and reduced appetite are the most frequently reported effects for both, typically easing as the body adjusts to each dose increase.

Dose-dependent severity

Side effects tend to track with dose level rather than which peptide is used, which is why both follow a slow titration schedule.

Less common concerns

Gallbladder issues and pancreatitis are rare but reported for both. Anyone with a personal or family history of thyroid tumors should discuss either option with a clinician.

Lean mass loss tracks total weight lost

Roughly a quarter of the weight lost on either peptide is lean mass, which is in line with what's seen in most calorie-deficit weight-loss research, not a peptide-specific effect.

No clear head-to-head difference

Available trial data doesn't show tirzepatide causing significantly more or less muscle loss than semaglutide when comparable weight loss is achieved.

Resistance training and protein intake matter more

Research on GLP-1 therapies consistently points to strength training and adequate protein as the biggest levers for preserving muscle, regardless of which peptide is used.

Brand-name pricing

Mounjaro/Zepbound and Ozempic/Wegovy list prices are broadly comparable, typically running over $1,000/month without insurance, though manufacturer savings cards can lower out-of-pocket cost significantly.

Compounding rules tightened in 2026

Both drugs are off the FDA shortage list, so large-scale compounding is no longer broadly allowed — it's now mostly limited to patients with a documented medical need, like an ingredient allergy or a non-standard dose.

Compounded semaglutide & tirzepatide cost

Where still available, compounded semaglutide runs about $99–$178/month and compounded tirzepatide about $125–$278/month — both well under brand list price, though supply now varies by provider.

Insurance coverage varies

Coverage for either peptide depends heavily on the specific indication (diabetes vs. weight management) and the individual insurance plan.

Start low, even coming from a high dose

Most switch protocols start tirzepatide at 2.5–5 mg/week regardless of the semaglutide dose someone was previously on, then re-titrate from there to limit GI side effects.

Timing between doses

Most protocols pick up the new peptide on the next scheduled weekly dosing day rather than adding an extra dose or a long washout period, though individual timing should be discussed with a clinician.

Side effects can restart

Because tirzepatide activates an additional receptor pathway, some GI side effects (nausea, bloating) can reappear briefly during re-titration even after a person was fully adjusted to semaglutide.

Semaglutide has the longer cardiovascular track record

Semaglutide's cardiovascular benefit is backed by dedicated outcomes trials — SUSTAIN-6, PIONEER-6, and the large SELECT trial — that have already reported results. Tirzepatide's own dedicated cardiovascular outcomes trials (including NCT07619508 and NCT06980623) are still ongoing, so its heart-health data, while promising, is less mature than semaglutide's.

Same warnings apply to both

Both carry warnings around thyroid C-cell tumors (seen in animal studies), pancreatitis, and gallbladder issues, based on their shared hormone-receptor mechanism.

Longer track record for semaglutide

Semaglutide has been in clinical use longer than tirzepatide, giving it a slightly longer real-world safety record, though both are actively monitored post-approval.

If maximum average weight loss is the goal

Tirzepatide's dual-receptor mechanism is linked to greater average weight loss in head-to-head trial data, at the cost of a shorter approval track record.

If a longer safety track record matters more

Semaglutide has been studied and prescribed for longer, giving it a more established real-world safety record — including a more mature cardiovascular-outcomes evidence base — at a somewhat lower average effect size.

Neither is a casual research chemical

Both are FDA-approved prescription drugs. Research-grade versions sold online are labeled for research only and are not intended for self-administration.